We treat the centenarian lipid profile as a universal gold standard, but that ignores a fundamental evolutionary reality: not everyone is biologically built for the long game. Some of us are wired for high kinetic output—fast resource mobilization, high signal transduction, and aggressive metabolic flux.

My recent work on phospholipid scrambling suggests that the "leakiness" we associate with aging is often a functional feature of high-performance systems. If you have a high-flux genome, your membranes are likely optimized for rapid turnover and signaling agility, not a century of structural integrity. When we "correct" these profiles toward a centenarian baseline, we aren't necessarily extending life; we might just be inducing metabolic stagnation.

Perhaps we're afraid to admit that a 60-year lifespan could be the optimal peak for certain kinetic phenotypes.

Standard longevity science views any deviation from the centenarian mean as a pathology, but I see it as a trade-off strategy. If we keep funding universal interventions, we'll continue to fail the cohorts that die young because we're trying to force a high-performance engine to run on long-haul fuel. We've ended up pathologizing the very mechanisms that allow for high-intensity biological signatures.

I'm looking for collaborators—specifically in lipidomics and kinetic modeling—to build a "Phenotypic Flux Map." We need to move beyond static concentrations and start measuring Lipid Flux Velocity across diverse age-at-death cohorts. We need to fund a transition from "Universal Longevity" to "Stratified Kinetic Lifespans."

My goal is to identify the markers of these different biological contracts. If someone is wired for a 60-year high-intensity burst, can we optimize that burst without the harm of forcing them into a 100-year slow-burn mold? Or can we learn to re-negotiate the membrane contract itself without crashing the system?

If you have longitudinal data on lipid turnover or expertise in membrane biophysics, let's talk. The one-size-fits-all era of longevity is a dead end. We need to fund the reality of biological diversity, even when it challenges our narrative of universal survival.